Munson Healthcare will soon be piloting a program to provide a one-time infusion of Bamlanivimab/Etesevimab combination to qualifying high-risk* non-hospitalized outpatients diagnosed with COVID-19 according to the FDA Fact Sheet for providers.
The first pilot will be in the Kalkaska Memorial Health Center Emergency Department. Please do NOT send your patients to KMHC for monoclonal antibody treatment as we are working to schedule specific times for the pilot.
*High risk is defined as patients who meet at least one of the following criteria:
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have
- cardiovascular disease, OR
- hypertension, OR
- chronic obstructive pulmonary disease/other chronic respiratory disease